메뉴 건너뛰기




Volumn 81, Issue 5, 2010, Pages 391-400

An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables

Author keywords

24 4 day regimen; Carbohydrate metabolism; Chlormadinone acetate; Hemostasis; Lipids; Low dose combined oral contraceptive; Low dose ethinylestradiol; Oral contraception

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C PEPTIDE; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CHOLESTEROL; D DIMER; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 77950859661     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.12.005     Document Type: Article
Times cited : (14)

References (47)
  • 1
    • 0025573030 scopus 로고
    • Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism
    • Gerstman B., Piper J., Freiman J., et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19 (1990) 931-936
    • (1990) Int J Epidemiol , vol.19 , pp. 931-936
    • Gerstman, B.1    Piper, J.2    Freiman, J.3
  • 2
    • 0026078062 scopus 로고
    • Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
    • Gerstman B., Piper J., Tomita D., Ferguson W., Stadel B., and Lundin F. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
    • (1991) Am J Epidemiol , vol.133 , pp. 32-37
    • Gerstman, B.1    Piper, J.2    Tomita, D.3    Ferguson, W.4    Stadel, B.5    Lundin, F.6
  • 4
    • 13344260005 scopus 로고
    • Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
    • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
    • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588
    • (1995) Lancet , vol.346 , pp. 1582-1588
  • 5
    • 0029609256 scopus 로고
    • Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
    • Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
    • (1995) Lancet , vol.346 , pp. 1593-1596
    • Bloemenkamp, K.W.1    Rosendaal, F.R.2    Helmerhorst, F.M.3    Buller, H.R.4    Vandenbroucke, J.P.5
  • 6
    • 0029586002 scopus 로고
    • Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
    • Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
    • (1995) Lancet , vol.346 , pp. 1589-1593
    • Jick, H.1    Jick, S.S.2    Gurewich, V.3    Myers, M.W.4    Vasilakis, C.5
  • 7
    • 0029671042 scopus 로고    scopus 로고
    • Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
    • Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
    • (1996) BMJ , vol.312 , pp. 83-88
    • Spitzer, W.O.1    Lewis, M.A.2    Heinemann, L.A.3    Thorogood, M.4    MacRae, K.D.5
  • 8
    • 0034070719 scopus 로고    scopus 로고
    • A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives
    • Farmer R., Lawrenson R., Todd J., et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49 (2000) 580-590
    • (2000) Br J Clin Pharmacol , vol.49 , pp. 580-590
    • Farmer, R.1    Lawrenson, R.2    Todd, J.3
  • 9
    • 0033028472 scopus 로고    scopus 로고
    • Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database
    • Todd J., Lawrenson R., Farmer R., Williams T., and Leydon G. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 14 (1999) 1500-1505
    • (1999) Hum Reprod , vol.14 , pp. 1500-1505
    • Todd, J.1    Lawrenson, R.2    Farmer, R.3    Williams, T.4    Leydon, G.5
  • 10
    • 0033709889 scopus 로고    scopus 로고
    • Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism
    • discussion 37S-38S
    • Winkler U. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 62 (2000) 11S-20S discussion 37S-38S
    • (2000) Contraception , vol.62
    • Winkler, U.1
  • 11
    • 69949088549 scopus 로고    scopus 로고
    • Hormonal contraception and risk of venous thromboembolism: national follow-up study
    • Lidegaard O., Lokkegaard E., Svendsen A.L., and Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339 (2009) b2890
    • (2009) BMJ , vol.339
    • Lidegaard, O.1    Lokkegaard, E.2    Svendsen, A.L.3    Agger, C.4
  • 12
    • 69949103268 scopus 로고    scopus 로고
    • The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
    • van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., and Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339 (2009) b2921
    • (2009) BMJ , vol.339
    • van Hylckama Vlieg, A.1    Helmerhorst, F.M.2    Vandenbroucke, J.P.3    Doggen, C.J.4    Rosendaal, F.R.5
  • 13
    • 0036237681 scopus 로고    scopus 로고
    • Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study
    • Schramm G., and Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 22 (2002) 221-231
    • (2002) Clin Drug Invest , vol.22 , pp. 221-231
    • Schramm, G.1    Steffens, D.2
  • 14
    • 0037383049 scopus 로고    scopus 로고
    • A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties
    • Schramm G., and Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 67 (2003) 305-312
    • (2003) Contraception , vol.67 , pp. 305-312
    • Schramm, G.1    Steffens, D.2
  • 15
    • 0031958753 scopus 로고    scopus 로고
    • Efficacy and safety of the new antiandrogenic oral contraceptive Belara
    • Zahradnik H.P., Goldberg J., and Andreas J.O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57 (1998) 103-109
    • (1998) Contraception , vol.57 , pp. 103-109
    • Zahradnik, H.P.1    Goldberg, J.2    Andreas, J.O.3
  • 16
    • 41549091883 scopus 로고    scopus 로고
    • Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study
    • Zahradnik H.P., and Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 77 (2008) 337-343
    • (2008) Contraception , vol.77 , pp. 337-343
    • Zahradnik, H.P.1    Hanjalic-Beck, A.2
  • 17
    • 1842689291 scopus 로고    scopus 로고
    • Ethinylestradiol/chlormadinone acetate
    • [discussion 61-2]
    • Curran M.P., and Wagstaff A.J. Ethinylestradiol/chlormadinone acetate. Drugs 64 (2004) 751-760 [discussion 61-2]
    • (2004) Drugs , vol.64 , pp. 751-760
    • Curran, M.P.1    Wagstaff, A.J.2
  • 18
    • 0034838348 scopus 로고    scopus 로고
    • Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon)
    • Worret I., Arp W., Zahradnik H.P., Andreas J.O., and Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203 (2001) 38-44
    • (2001) Dermatology , vol.203 , pp. 38-44
    • Worret, I.1    Arp, W.2    Zahradnik, H.P.3    Andreas, J.O.4    Binder, N.5
  • 19
    • 29044442795 scopus 로고    scopus 로고
    • Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea
    • Zahradnik H.P. Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 10 Suppl 1 (2005) 12-18
    • (2005) Eur J Contracept Reprod Health Care , vol.10 , Issue.SUPPL. 1 , pp. 12-18
    • Zahradnik, H.P.1
  • 21
    • 85052549916 scopus 로고
    • Combined oral contraceptives. A statement by the Committee on Safety of Drugs
    • Combined oral contraceptives. A statement by the Committee on Safety of Drugs. Br Med J 2 (1970) 231-232
    • (1970) Br Med J , vol.2 , pp. 231-232
  • 22
    • 84975926180 scopus 로고
    • R.C.O.G. statement on oral contraceptives
    • Jeffcoate T.N. R.C.O.G. statement on oral contraceptives. Br Med J 2 (1970) 293
    • (1970) Br Med J , vol.2 , pp. 293
    • Jeffcoate, T.N.1
  • 24
    • 0030222154 scopus 로고    scopus 로고
    • Shorter pill-free interval in combined oral contraceptives decreases follicular development
    • Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
    • (1996) Contraception , vol.54 , pp. 71-77
    • Spona, J.1    Elstein, M.2    Feichtinger, W.3
  • 25
    • 0033168809 scopus 로고    scopus 로고
    • Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity
    • Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72 (1999) 115-120
    • (1999) Fertil Steril , vol.72 , pp. 115-120
    • Sullivan, H.1    Furniss, H.2    Spona, J.3    Elstein, M.4
  • 28
    • 0012431804 scopus 로고    scopus 로고
    • Report of the expert committee on the diagnosis and classification of diabetes mellitus
    • Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S5-S20
    • (2003) Diabetes Care , vol.26 , Issue.SUPPL. 1
  • 29
    • 0031851293 scopus 로고    scopus 로고
    • Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
    • Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
    • (1998) Diabet Med , vol.15 , pp. 539-553
    • Alberti, K.G.1    Zimmet, P.Z.2
  • 30
    • 19444379341 scopus 로고    scopus 로고
    • Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
    • Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
    • (2005) Contraception , vol.71 , pp. 409-416
    • Klipping, C.1    Marr, J.2
  • 31
    • 0037369726 scopus 로고    scopus 로고
    • The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study
    • The Oral Contraceptive and Hemostasis Study Group
    • The Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 67 (2003) 173-185
    • (2003) Contraception , vol.67 , pp. 173-185
  • 32
    • 33644862743 scopus 로고    scopus 로고
    • A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol
    • Kluft C., Endrikat J., Mulder S.M., Gerlinger C., and Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 73 (2006) 336-343
    • (2006) Contraception , vol.73 , pp. 336-343
    • Kluft, C.1    Endrikat, J.2    Mulder, S.M.3    Gerlinger, C.4    Heithecker, R.5
  • 33
    • 33644817742 scopus 로고    scopus 로고
    • Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters
    • Aldrighi J.M., De Campos L.S., Eluf Gebara O.C., Petta C.A., and Bahamondes L. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters. Gynecol Endocrinol 22 (2006) 1-4
    • (2006) Gynecol Endocrinol , vol.22 , pp. 1-4
    • Aldrighi, J.M.1    De Campos, L.S.2    Eluf Gebara, O.C.3    Petta, C.A.4    Bahamondes, L.5
  • 34
    • 22044452540 scopus 로고    scopus 로고
    • A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel
    • Jespersen J., Endrikat J., Dusterberg B., et al. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. Contraception 72 (2005) 98-104
    • (2005) Contraception , vol.72 , pp. 98-104
    • Jespersen, J.1    Endrikat, J.2    Dusterberg, B.3
  • 35
    • 34047263992 scopus 로고    scopus 로고
    • The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    • Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
    • (2007) Contraception , vol.75 , pp. 344-354
    • Dinger, J.C.1    Heinemann, L.A.2    Kuhl-Habich, D.3
  • 36
    • 0030866776 scopus 로고    scopus 로고
    • Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group
    • Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception 55 (1997) 219-224
    • (1997) Contraception , vol.55 , pp. 219-224
    • Crook, D.1
  • 37
    • 1642329996 scopus 로고    scopus 로고
    • A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles
    • Gaspard U., Endrikat J., Desager J.P., Buicu C., Gerlinger C., and Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69 (2004) 271-278
    • (2004) Contraception , vol.69 , pp. 271-278
    • Gaspard, U.1    Endrikat, J.2    Desager, J.P.3    Buicu, C.4    Gerlinger, C.5    Heithecker, R.6
  • 38
    • 0035068298 scopus 로고    scopus 로고
    • Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel
    • Knopp R.H., Broyles F.E., Cheung M., Moore K., Marcovina S., and Chandler W.L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 63 (2001) 1-11
    • (2001) Contraception , vol.63 , pp. 1-11
    • Knopp, R.H.1    Broyles, F.E.2    Cheung, M.3    Moore, K.4    Marcovina, S.5    Chandler, W.L.6
  • 39
    • 0024561955 scopus 로고
    • Oral contraceptives and lipids
    • Fotherby K. Oral contraceptives and lipids. BMJ 298 (1989) 1049-1050
    • (1989) BMJ , vol.298 , pp. 1049-1050
    • Fotherby, K.1
  • 40
    • 0028089149 scopus 로고
    • Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone
    • Akerlund M., Almstrom E., Hogstedt S., and Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 73 (1994) 136-143
    • (1994) Acta Obstet Gynecol Scand , vol.73 , pp. 136-143
    • Akerlund, M.1    Almstrom, E.2    Hogstedt, S.3    Nabrink, M.4
  • 41
    • 0031852621 scopus 로고    scopus 로고
    • Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette
    • Berga S.L. Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette. Am J Obstet Gynecol 179 (1998) S9-17
    • (1998) Am J Obstet Gynecol , vol.179
    • Berga, S.L.1
  • 42
    • 0034772212 scopus 로고    scopus 로고
    • Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation
    • Kemmeren J.M., Algra A., and Grobbee D.E. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 250 (2001) 441-448
    • (2001) J Intern Med , vol.250 , pp. 441-448
    • Kemmeren, J.M.1    Algra, A.2    Grobbee, D.E.3
  • 43
    • 0036210707 scopus 로고    scopus 로고
    • An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables
    • Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65 (2002) 215-221
    • (2002) Contraception , vol.65 , pp. 215-221
    • Endrikat, J.1    Klipping, C.2    Cronin, M.3
  • 44
    • 0842324636 scopus 로고    scopus 로고
    • Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism
    • Scharnagl H., Petersen G., Nauck M., Teichmann A.T., Wieland H., and Marz W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 69 (2004) 105-113
    • (2004) Contraception , vol.69 , pp. 105-113
    • Scharnagl, H.1    Petersen, G.2    Nauck, M.3    Teichmann, A.T.4    Wieland, H.5    Marz, W.6
  • 45
    • 0037501322 scopus 로고    scopus 로고
    • A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism
    • Gaspard U., Scheen A., Endrikat J., et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 67 (2003) 423-429
    • (2003) Contraception , vol.67 , pp. 423-429
    • Gaspard, U.1    Scheen, A.2    Endrikat, J.3
  • 46
    • 0242286063 scopus 로고    scopus 로고
    • Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism
    • Ludicke F., Gaspard U.J., Demeyer F., Scheen A., and Lefebvre P. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception 66 (2002) 411-415
    • (2002) Contraception , vol.66 , pp. 411-415
    • Ludicke, F.1    Gaspard, U.J.2    Demeyer, F.3    Scheen, A.4    Lefebvre, P.5
  • 47
    • 0037228146 scopus 로고    scopus 로고
    • Progestogens with antiandrogenic properties
    • Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492
    • (2003) Drugs , vol.63 , pp. 463-492
    • Raudrant, D.1    Rabe, T.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.